Zealand Pharma Will Test European IPO Market
This article was originally published in The Pink Sheet Daily
Executive Summary
The Danish biotech hopes to tempt investors with revenue prospects from its late-stage GLP-1 analog, partnered with Sanofi-Aventis.
You may also be interested in...
Chiesi Buys Denmark’s Zymenex For Phase III Enzyme Replacement Therapy
The purchase of Zymenex by Italy’s Chiesi has allowed VC firm Sunstone Capital to reap a second return on its investment in the Danish developer of enzyme replacement therapies.
France's Adocia Completes 2012's First Euro Biotech IPO
French drug delivery company, Adocia, raises $33 million to develop new formulations of therapeutic proteins for wound healing, diabetes
Boehringer Enhances Diabetes Pipeline With Zealand's GLP-1/Glucagon Agonist
Boehringer wins global rights to Zealand's Phase I-ready novel diabetes compound, pledging €20 million during 2011.